Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2001 - 2025 of 15133 in total
Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence...
Approved
Investigational
Matched Description: … was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid ... Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] ... Some small modifications where performed in this inactive compound and with the creation of rifamycin …
Matched Categories: … Alimentary Tract and Metabolism …
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection...
Approved
Investigational
Matched Iupac: … methoxy)ethoxy]ethyl}carbamoyl)methoxy]ethoxy}ethyl)carbamoyl]-1-carboxypropyl]carbamoyl}heptadecanoic acid
Matched Description: … and reducing blood glucose. ... [A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. ... 1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942]...
Approved
Investigational
Matched Description: … , and serotonin. ... [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), ... and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. …
Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and mutant transthyretin (TTR) messenger RNA (mRNA). This siRNA therapeutic is indicated for the treatment of neuropathies associated with hereditary transthyretin-mediated amyloidosis (ATTR), a condition caused by mutations in the TTR gene. More than 130 TTR mutations have...
Approved
Investigational
Matched Description: … Vutrisiran is a double-stranded small interfering ribonucleic acid (siRNA) that targets wild-type and ... [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows ... prevalent among hereditary ATTR patients with polyneuropathy, especially in Portugal, France, Sweden, and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin . This specific property of the molecule inspired workers to study...
Approved
Matched Description: … Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase ... its penetration and efficacy [L1979]. ... Adverse effects of anthralin include irritation and discoloration of the skin [A27277]. …
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved
Matched Description: … 13-cis-retinoic acid (RA). ... [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and ... within neuroblastomas (and other neuroectodermal tumors),[A224609] and is rarely subject to antigen …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Bordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and Fim3).
Approved
Investigational
Matched Description: … pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct fimbriae (Fim2 and
Matched Mixtures name: … FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and
Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Approved
Matched Categories: … Alimentary Tract and Metabolism ... oxyphencyclimine and psycholeptics …
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC...
Approved
Matched Description: … A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018. ... [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[ ... dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and
Matched Categories: … Alimentary Tract and Metabolism …
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Withdrawn
Matched Description: … Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. ... into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. ... categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor...
Approved
Investigational
Matched Description: … extensively investigated as an immunosuppressive and antitumour agent. ... [A242412] It was first isolated and identified as an antifungal agent with potent anticandida activity ... ; however, after its potent antitumor and immunosuppressive activities were later discovered, it was …
Matched Categories: … Sirolimus and Prodrugs ... Antineoplastic and Immunomodulating Agents …
Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).
Approved
Investigational
Matched Description: … Pneumonia and Chronic Obstructive Pulmonary Disease (COPD). ... Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated …
Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication.[A4017,A263041] It was...
Approved
Investigational
Matched Description: … Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the Band has a potency of 2-3 times higher than ... [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Approved
Investigational
Matched Categories: … Drugs for Acid Related Disorders ... Alimentary Tract and Metabolism ... omeprazole, amoxicillin and rifabutin ... Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) …
A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Approved
Nutraceutical
Matched Description: … A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted …
Matched Categories: … Blood and Blood Forming Organs ... Diet, Food, and Nutrition …
Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. ... Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ... antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible for this treatment...
Approved
Investigational
Matched Description: … Food and Drug Administration on August 1, 2017. ... First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. ... This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.
Approved
Investigational
Vet approved
Matched Description: … GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Nafarelin is a potent synthetic agonist of gonadotropin-releasing hormone with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central precocious puberty and endometriosis.
Approved
Matched Description: … Nafarelin has been used in the treatments of central precocious puberty and endometriosis. …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Gonadotropins and Antigonadotropins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Approved
Investigational
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Approved
Investigational
Matched Description: … Tipranavir and ritonavir are coadministered to treat HIV. ... Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets …
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first...
Approved
Investigational
Matched Description: … Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and ... offering a similar side effect profile and efficacy to previous formulations of ropinirole [A35711]. ... capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and
A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing...
Approved
Investigational
Matched Description: … use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and ... technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and
Matched Categories: … Ergot Alkaloids and Derivatives …
Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. The LAMA group falls into a...
Approved
Investigational
Matched Description: … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] ... The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type ... labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human...
Approved
Matched Description: … It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous ... [L40719] It has a number of therapeutic uses, including the management and prevention of infections and ... G-CSF and has an N-terminal methionine added in the sequence for expression in _E. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 2001 - 2025 of 15133 in total